AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Thursday 29 October 2026
News from the 24 hours to Thursday morning, 29 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly mildly positive, led by an EU approval for Enhertu, reports that the company is weighing a move into cancer vaccines and awareness and recognition stories. One commentary piece on a bruising summer and a neutral Deutsche Bank rating held back the score ahead of third-quarter results.
What drove it
- Enhertu EU approval
- cancer vaccine plans
- Q3 results ahead
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
10 stories · 13 headlines · strongest first
Pharma and healthcare on 29 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results preview for 30 October +3.02 headlines today · 7 in all, since 24 October · Previews expect $2.60 a share earnings, and note EU approval of Enhertu. | ||
| +6.7 | European approval of a cancer drug, with earnings approaching. | |
| +0.8 | Routine preview of expected quarterly profit per share. | |
| Mark-Paul Gosselaar and AstraZeneca begin Meet Your Mark cancer biomarker testing campaign +3.82 headlines today · AstraZeneca and Gosselaar launched a cancer biomarker testing awareness campaign. | ||
| +4.2 | Awareness campaign on biomarker testing with a celebrity; mildly positive brand activity. | |
| +3.3 | Interview tied to company-backed testing awareness campaign. | |
| AstraZeneca CEO says company may develop cancer vaccines +3.72 headlines today · 7 in all, since 28 October · Outlets report AstraZeneca weighing a move into cancer vaccines. | ||
| +3.3 | Company reportedly exploring expansion into a reviving therapeutic area. | |
| +3.3 | Report of possible diversification into a revived treatment field. | |
| AstraZeneca summer setbacks raise stakes for 2027 −5.81 headline today · Endpoints says AstraZeneca's summer has increased what is at stake in 2027. | ||
| −5.8 | Commentary says a difficult summer leaves more pressure for next year. | |
| AstraZeneca valuation versus cash flow +3.31 headline today · A piece says AstraZeneca stock trades below its cash flow value. | ||
| +3.3 | Valuation commentary suggests shares look inexpensive relative to cash generation. | |
| AstraZeneca executive on turning science into patient outcomes +3.31 headline today · Nancy Ghattas highlights AstraZeneca's efforts to translate science into outcomes. | ||
| +3.3 | Executive profile emphasising research translating into patient benefit. | |
| AstraZeneca Egypt listed among best workplaces for inclusion in 2026 +3.31 headline today · AstraZeneca Egypt received a 2026 inclusion workplace award. | ||
| +3.3 | Regional subsidiary recognised for inclusive workplace. | |
| AstraZeneca shows its oncology pipeline at the 2026 ESMO congress +7.11 headline today · 15 in all, since 26 October · AstraZeneca presented at the ESMO congress. | ||
| +2.5 | Company presenting at major oncology conference; routine but constructive. | |
| AstraZeneca shares hold near support level +1.71 headline today · A piece says the stock is steady near GBX12,824. | ||
| +1.7 | Share price stable with buyers holding a support level. | |
| Deutsche Bank stays Neutral on AstraZeneca 0.01 headline today · Deutsche Bank kept its Neutral rating. | ||
| 0.0 | Broker keeps a middling rating, no change in view. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.